Dicarbonyl/L-xylulose reductase

A potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma

Jeong Hee Cho, Spiridon Tsavachidis, Kim Anh Do, Junichi Nakagawa, L. Jeffrey Medeiros, Timothy J. McDonnell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To identify genes involved in prostate carcinogenesis, we used laser-capture microdissection-micro serial analysis of gene expression to construct libraries of paired cancer and normal cells from human tissue samples. After computational comparison of the two libraries, we identified dicarbonyl/L-xylulose reductase (DCXR), an enzyme that catalyzes A-dicarbonyl and L-xylulose, as being significantly up-regulated in prostate cancer cells. The specificity of DCXR up-regulation for prostate cancer tissues was confirmed by quantitative real-time reverse transcriptase-PCR, virtual Northern blot, and Western blot analyses. Furthermore, DCXR expression at the protein level was assessed using fresh-frozen tissues and a tissue microarray consisting of 46 cases of organ-confined early-stage prostate cancer and 29 cases of chemohormonally treated prostate cancer. In most normal prostate epithelial cells, DCXR was expressed at low levels and was localized predominantly in the cytoplasmic membrane. In contrast, in virtually all grades of early-stage prostate cancer and in all chemohormonally treated cases, DCXR was strikingly overexpressed and was localized predominantly in the cytoplasm and nucleus. In all samples, the stromal cells were completely devoid of DCXR expression. Based on these findings, we suggest that DCXR overexpression has the potential to be an additional useful biomarker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)2615-2622
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Laser Capture Microdissection
Prostate
Adenocarcinoma
Biomarkers
Prostatic Neoplasms
Gene Expression
Libraries
Xylulose
Stromal Cells
L-xylulose reductase
Reverse Transcriptase Polymerase Chain Reaction
Northern Blotting
Real-Time Polymerase Chain Reaction
Carcinogenesis
Cytoplasm
Up-Regulation
Western Blotting
Epithelial Cells
Cell Membrane
Enzymes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Dicarbonyl/L-xylulose reductase : A potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. / Cho, Jeong Hee; Tsavachidis, Spiridon; Do, Kim Anh; Nakagawa, Junichi; Medeiros, L. Jeffrey; McDonnell, Timothy J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 12, 01.12.2007, p. 2615-2622.

Research output: Contribution to journalArticle

@article{61ae8eacb933476aad8fc41330adea40,
title = "Dicarbonyl/L-xylulose reductase: A potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma",
abstract = "To identify genes involved in prostate carcinogenesis, we used laser-capture microdissection-micro serial analysis of gene expression to construct libraries of paired cancer and normal cells from human tissue samples. After computational comparison of the two libraries, we identified dicarbonyl/L-xylulose reductase (DCXR), an enzyme that catalyzes A-dicarbonyl and L-xylulose, as being significantly up-regulated in prostate cancer cells. The specificity of DCXR up-regulation for prostate cancer tissues was confirmed by quantitative real-time reverse transcriptase-PCR, virtual Northern blot, and Western blot analyses. Furthermore, DCXR expression at the protein level was assessed using fresh-frozen tissues and a tissue microarray consisting of 46 cases of organ-confined early-stage prostate cancer and 29 cases of chemohormonally treated prostate cancer. In most normal prostate epithelial cells, DCXR was expressed at low levels and was localized predominantly in the cytoplasmic membrane. In contrast, in virtually all grades of early-stage prostate cancer and in all chemohormonally treated cases, DCXR was strikingly overexpressed and was localized predominantly in the cytoplasm and nucleus. In all samples, the stromal cells were completely devoid of DCXR expression. Based on these findings, we suggest that DCXR overexpression has the potential to be an additional useful biomarker for prostate cancer.",
author = "Cho, {Jeong Hee} and Spiridon Tsavachidis and Do, {Kim Anh} and Junichi Nakagawa and Medeiros, {L. Jeffrey} and McDonnell, {Timothy J.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1055-9965.EPI-07-0684",
language = "English (US)",
volume = "16",
pages = "2615--2622",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Dicarbonyl/L-xylulose reductase

T2 - A potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma

AU - Cho, Jeong Hee

AU - Tsavachidis, Spiridon

AU - Do, Kim Anh

AU - Nakagawa, Junichi

AU - Medeiros, L. Jeffrey

AU - McDonnell, Timothy J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - To identify genes involved in prostate carcinogenesis, we used laser-capture microdissection-micro serial analysis of gene expression to construct libraries of paired cancer and normal cells from human tissue samples. After computational comparison of the two libraries, we identified dicarbonyl/L-xylulose reductase (DCXR), an enzyme that catalyzes A-dicarbonyl and L-xylulose, as being significantly up-regulated in prostate cancer cells. The specificity of DCXR up-regulation for prostate cancer tissues was confirmed by quantitative real-time reverse transcriptase-PCR, virtual Northern blot, and Western blot analyses. Furthermore, DCXR expression at the protein level was assessed using fresh-frozen tissues and a tissue microarray consisting of 46 cases of organ-confined early-stage prostate cancer and 29 cases of chemohormonally treated prostate cancer. In most normal prostate epithelial cells, DCXR was expressed at low levels and was localized predominantly in the cytoplasmic membrane. In contrast, in virtually all grades of early-stage prostate cancer and in all chemohormonally treated cases, DCXR was strikingly overexpressed and was localized predominantly in the cytoplasm and nucleus. In all samples, the stromal cells were completely devoid of DCXR expression. Based on these findings, we suggest that DCXR overexpression has the potential to be an additional useful biomarker for prostate cancer.

AB - To identify genes involved in prostate carcinogenesis, we used laser-capture microdissection-micro serial analysis of gene expression to construct libraries of paired cancer and normal cells from human tissue samples. After computational comparison of the two libraries, we identified dicarbonyl/L-xylulose reductase (DCXR), an enzyme that catalyzes A-dicarbonyl and L-xylulose, as being significantly up-regulated in prostate cancer cells. The specificity of DCXR up-regulation for prostate cancer tissues was confirmed by quantitative real-time reverse transcriptase-PCR, virtual Northern blot, and Western blot analyses. Furthermore, DCXR expression at the protein level was assessed using fresh-frozen tissues and a tissue microarray consisting of 46 cases of organ-confined early-stage prostate cancer and 29 cases of chemohormonally treated prostate cancer. In most normal prostate epithelial cells, DCXR was expressed at low levels and was localized predominantly in the cytoplasmic membrane. In contrast, in virtually all grades of early-stage prostate cancer and in all chemohormonally treated cases, DCXR was strikingly overexpressed and was localized predominantly in the cytoplasm and nucleus. In all samples, the stromal cells were completely devoid of DCXR expression. Based on these findings, we suggest that DCXR overexpression has the potential to be an additional useful biomarker for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=38849098902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849098902&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-07-0684

DO - 10.1158/1055-9965.EPI-07-0684

M3 - Article

VL - 16

SP - 2615

EP - 2622

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -